Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PRNP | P04156 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13269047 | 0.88 | CYP3A4 (0.48) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL10157235 | 0.86 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2LMNAPRNP | |
| SCHEMBL13269339 | 0.84 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2LMNAPRNP | |
| SCHEMBL13269636 | 0.80 | NPSR1 (0.42) | MEN1KMT2ASMN1; SMN2LMNAPRNP | |
| SCHEMBL12992704 | 0.77 | MEN1 (0.47) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL13268958 | 0.76 | SMN1; SMN2 (0.52) | MEN1KMT2ASMN1; SMN2LMNAPRNP | |
| SCHEMBL10157239 | 0.75 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL17280558 | 0.75 | CYP3A4 (0.47) | MEN1KMT2ASMN1; SMN2LMNAPRNP | |
| SCHEMBL10157230 | 0.73 | CYP3A4 (0.48) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL16258491 | 0.73 | CYP3A4 (0.48) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511273-B1 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | HIVIH (FR) | 2019-05-15 | — | — | EP | disclosed |
| EP-2697213-B1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | HIVIH (FR) | 2018-12-12 | — | — | EP | disclosed |
| US-9604900-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2017-03-28 | — | — | US | disclosed |
| US-9604900-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2017-03-28 | — | — | US | disclosed |
| US-9604900-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2017-03-28 | — | — | US | disclosed |
| EP-2697213-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-02-19 | — | — | EP | disclosed |
| US-20140031338-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031338-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031338-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-01-30 | — | — | US | disclosed |
| WO-2012140243-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012140243-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2012-10-18 | — | — | WO | disclosed |
| EP-2511273-A1 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2012-10-17 | — | — | EP | disclosed |
| EP-2511273-A1 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2012-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031338-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | POLRMT, MAVS, EIF2AK2 | MEN1 4591/4885KMT2A 2560/4885SMN1; SMN2 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.